Teva Pharmaceuticals working on billon dollar bid to take over Mylan

April 21, 2015 17:35


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Bloomberg reports that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) could publish a bid for its US rival Mylan Inc. (MYL) today, in what could turn out to be the largest deal of the year in pharmaceuticals.

Citing sources familiar with the matter, Bloomberg says that Teva is working with Barclays Bank on a takeover bid for Mylan, which has a current market cap of $33.3 billion, and is in touch with other banks on finance for such a deal.

According to the report, Teva is working on the final stages of a bid, although it is possible that in the end the move will not go ahead.

Related Content

Breaking news
July 17, 2018
Netanyahu takes credit for Trump leaving Iran Deal